文献速递糖尿病

2011-2021年美国成人糖尿病患者的胰高血糖素处方与费用

Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011-2021.
PubMed 文献 · Diabetes Care · 2023-01-01

这项回顾性队列研究分析了2011年1月1日至2021年3月31日OptumLabs数据仓库中2,814,464例成人糖尿病患者,发现胰高血糖素总体配药率从2.91降至2.28/1000人年(-22%),但在1型糖尿病、使用短效胰岛素或有严重低血糖史的高危亚组中上升;商业保险和Medicare Advantage受益人的单位总费用分别上涨74%和95%。

要点

  • 胰高血糖素总体配药率从2.91降至2.28/1000人年(-22%)。
  • 1型糖尿病、使用短效胰岛素、有严重低血糖史者配药率分别上升64%、43%、25%。
  • 商业保险和Medicare Advantage受益人单位总费用分别上涨74%和95%。

核心结论

  • 胰高血糖素配药率总体偏低且在2011至2021年间下降,但在1型糖尿病、使用短效胰岛素或有严重低血糖史的高危亚组中上升。
  • 少数族裔患者和低收入人群的配药率不成比例地低。

研究设计与样本

  • 回顾性队列研究,纳入OptumLabs数据仓库中2011年1月1日至2021年3月31日的2,814,464例成人糖尿病患者,平均年龄62.8岁(SD 13.2)。

主要发现

  • 总体胰高血糖素配药率从2.91降至2.28/1000人年(-22%)。
  • 1型糖尿病患者配药率从22.46升至36.76/1000人年(64%)。
  • 使用短效胰岛素者配药率从11.64升至16.63/1000人年(43%)。
  • 有严重低血糖史者配药率从16.08升至20.12/1000人年(25%)。
  • 商业保险受益人单位总费用从157.97美元升至275.32美元(74%),Medicare Advantage受益人从150.37美元升至293.57美元(95%)。

关键数值与推荐

  • 白人患者、女性、高收入者和商业保险患者的胰高血糖素配药率分别高于少数族裔患者、男性、低收入者和Medicare Advantage患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize contemporary trends in glucagon fill rates and expenditures in a nationwide cohort of adults with diabetes overall and by key demographic and clinical characteristics. RESEARCH DESIGN AND METHODS: In this retrospective cohort study, we examined 1) glucagon fill rates per 1,000 person-years and 2) patient out-of-pocket and health plan costs per filled glucagon dose among adults with diabetes included in OptumLabs Data Warehouse between 1 January 2011 and 31 March 2021. RESULTS: The study population comprised 2,814,464 adults with diabetes with a mean age of 62.8 (SD 13.2) years. The overall glucagon fill rate decreased from 2.91 to 2.28 per 1,000 person-years (-22%) over the study period. In groups at high risk for severe hypoglycemia, glucagon fill rates increased from 22.46 to 36.76 per 1,000 person-years (64%) among patients with type 1 diabetes, 11.64 to 16.63 per 1,000 person-years (43%) among those treated with short-acting insulin, and 16.08 to 20.12 per 1,000 person-years (25%) among those with a history of severe hypoglycemia. White patients, women, individuals with high income, and commercially insured patients had higher glucagon fill rates compared with minority patients, males, individuals with low income, and Medicare Advantage patients, respectively. Total cost per dosing unit increased from $157.97 to $275.32 (74%) among commercial insurance beneficiaries and from $150.37 to $293.57 (95%) among Medicare Advantage beneficiaries. CONCLUSIONS: Glucagon fill rates are concerningly low and declined between 2011 and 2021 but increased in appropriate subgroups with type 1 diabetes, using short-acting insulin, or with a history of severe hypoglycemia. Fill rates were disproportionately low among minority patients and individuals with low income.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Herges JR, Galindo RJ, Neumiller JJ, et al. Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011-2021. Diabetes Care. 2023. PMID: 36630526. doi:10.2337/dc22-1564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。